[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568010":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":25,"locations":34,"responsibleParty":54,"collaborators":10,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":10,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":10,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients undergo standard of care treatment with ipilimumab\u002Fnivolumab and answer questions and enter symptoms in the mobile Vigilant application. Patients wearing a compatible watch have their vital signs recorded at the same time symptoms are being entered. Based on the severity of symptoms, patients may be recommended to reach out to their healthcare team or to go to the emergency room. Additionally, patients complete a survey and may have their medical charts reviewed on study.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Non-Interventional Study","Non-Interventional study",[9],[20,23],{"name":21,"affiliation":5,"role":22},"Svetomir N. Markovic, MD, PhD","PRINCIPAL_INVESTIGATOR",{"name":24,"affiliation":5,"role":22},"Lisa A. Kottschade, APRN, CNP",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":10},"Renee Bradshaw","507-284-2511",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Mayo Clinic in Rochester","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-92.4699,44.02163,{"lat":47,"lon":46},[50,51,52,53],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},{"name":32,"role":28,"phone":33,"phoneExt":10,"email":10},{"name":21,"role":22,"phone":10,"phoneExt":10,"email":10},{"name":24,"role":22,"phone":10,"phoneExt":10,"email":10},{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100568010","digital-remote-monitoring-of-immune-checkpoint-inhibitor-therapy-induced-toxicity-using-the-vigilant-app-100568010",false,"NCT06675643","Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App","Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity: A Feasibility Study of the Vigilant App (Vigilant-2)","Inclusion Criteria:\n\n* Any skin cancer\u002Fmelanoma patient starting dual \\[ipilimumab\u002Fnivolumab (IPI\u002FNIVO)\\] immune checkpoint inhibitor (ICI) therapy\n\nExclusion Criteria:\n\n* Does not meet inclusion criteria","ALL","18 Years",{"count":66,"type":67},100,"ESTIMATED","OBSERVATIONAL","This study is being done to better understand patient experiences with using a mobile application, known as Vigilant, to monitor symptoms as outpatients and to gather preliminary data on the potential clinical benefit to remote monitoring of adverse events.",[71,72],"Malignant Skin Neoplasm","Melanoma","2026-02-06",{"date":75,"type":76},"2026-02-10","ACTUAL",{"date":78,"type":76},"2024-10-14",{"date":80,"type":67},"2027-03-15",{"name":5,"class":6},1]